The guide includes information on a drug’s origin, common street names, how it is abused, what effect it has on the mind and body, what the overdose effects are, and what its legal status is in the US.
Chemical exposures reported to the National Poison Data System (NPDS) increased substantially in early March 2020, likely due to cleaning efforts related to coronavirus disease 2019 (COVID-19), according to a recent Morbidity and Mortality Weekly Report.
Novo Nordisk has launched its Diabetes Patient Assistance Program in response to the COVID-19 pandemic for patients with diabetes who have lost health insurance coverage due to a change in job status.
The Food and Drug Administration (FDA) is alerting healthcare professionals and consumers of a voluntary recall of 3 lots of Amneal’s Nizatidine Oral Solution (15mg/mL) due to potential contamination with N-Nitrosodimethylamine (NDMA), a probable human carcinogen.
The Centers for Disease Control and Prevention (CDC) released preliminary data related to outcomes among US patients with coronavirus disease 2019 (COVID-19).
The policy is intended to remain in effect only for the duration of the COVID-19 public health emergency declared by the Department of Health and Human Services (HHS).
The FDA announced that it is working closely with other government agencies and academic centers to investigate the potential use of chloroquine for the treatment of coronavirus disease 2019 (COVID-19).
Fresenius Kabi announced the launch of Glucagon Emergency Kit for the treatment of severe hypoglycemic episodes in adult and pediatric patients with diabetes.
The Food and Drug Administration (FDA) has approved Palforzia (Peanut [Arachis hypogaea] Allergen Powder-dnfp; Aimmune Therapeutics) for the treatment of peanut allergy.
In addition to a panel of experts, for the first time, the guideline was developed with the help of patients, emphasizing the importance of shared decision-making.
